April 2015 Vol. 7 Issue 4

Abstracts & Commentary

Essential Fatty Acids and Antioxidants Benefit Women With Female Pattern Hair Loss

by Sherry Torkos, RPh  A new study using essential fatty acids and antioxidants in women with female pattern hair loss found that these nutrients increased hair density and improved hair growth.

Can Laughter Therapy Reduce Radiation Dermatitis?

by Jacob Schor, ND, FABNO  According to this small study, laughter therapy alleviated symptoms of radiation dermatitis in breast-cancer patients, but in statistically nonsignificant ways. Should practitioners encourage laughter as therapy before larger clinical trials are performed?

Can Chondroitin and Glucosamine Rival Cox-2 Inhibitors for Osteoarthritis?

by Sarah Bedell Cook, ND  Surprising results of a European trial suggest a combination of chondroitin sulfate and glucosamine hydrochloride offers better pain relief for knee osteoarthritis than celecoxib.

Plant a Tree, Ditch the Antidepressants?

by Kurt Beil, ND, LAc, MPH  Greater density of trees in London neighborhoods had an inversion association with the use of antidepressant medication among residents in a recent cross-sectional analysis.

Vitamin C Aids Recovery From Cardiac Surgery

by Tina Kaczor, ND, FABNO  Vitamin C was shown in a recent study to have a profound effect on recovery from cardiac surgery, potentially offering a low-cost, safe way to improve outcomes.


Taking Food Sensitivity Testing to the Next Level

by Natural Medicine Journal In the first of 2 interviews, Dawna L. Jones, MD, FACOG, describes how she tests for food sensitivity in her clinical practice. She also discusses prevalence, symptomatology, and gives some advice on how to effectively diagnose food sensitivity issues. In the second interview, James White, chief executive officer of KBMO Diagnostics, describes how the FIT Test is different from other food sensitivity tests.

Peer-Reviewed Articles

N-Acetylglucosamine for Treatment of Inflammatory Bowel Disease

by Andy Z. X. Zhu, PhD  Inflammatory bowel disease (IBD) is associated with a widespread breakdown of glycosaminoglycans, which are normally attached to mucin and help to form a protective barrier separating bacteria from the intestinal epithelium. N-acetylglucosamine (NAG) is a naturally occurring amino sugar precursor for epithelial glycosaminoglycan synthesis. This pragmatic open-label clinical trial assessed the efficacy and safety of NAG and demonstrated that NAG could be an efficacious adjunctive treatment for IBD.